Broadvector Limited

Regenerative cell therapies are often touted as the future of medicine, and now, it seems that future can finally be talked about in terms of years instead of eons. In the past, investors have had a t

Biopharmaceutical, medical device, and in vitro diagnostics start-up dealmaking from July through September 2010. Data from Elsevier's Strategic Transactions. Deanna F. Kamienski Financings In the thi

In Vitro Diagnostics Acquisitions /In Vitro Diagnostics Cepheid Novartis AG Novartis AG has licensed exclusive rights to Cepheid 's (DNA analysis) Xpert BCR-ABL assay, which monitors the BCR-